Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

Xenon Pharmaceuticals is a Canadian biopharma company targeting neurological diseases with a focus on ion channel-blocking technology. The clinical stage asset, azetukalner, is in late stage ...

Questions may be submitted (via chat function) during the live webinar or submitted in advance via email to investors@xenon-pharma.com. Click to enlarge A live webcast of the webinar will be available ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...